Sarah Ketterer’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $375K | Sell |
7,163
-3,947
| -36% | -$209K | ﹤0.01% | 106 |
|
|
2026
Q1 | $613K | Sell |
11,110
-22,787
| -67% | -$1.23M | 0.01% | 90 |
|
|
2025
Q4 | $1.66M | Sell |
33,897
-1,143,104
| -97% | -$53.3M | 0.02% | 85 |
|
|
2025
Q3 | $50.8M | Buy |
1,177,001
+69,925
| +6% | +$2.73M | 0.67% | 36 |
|
|
2025
Q2 | $42.5M | Sell |
1,107,076
-847
| -0.1% | -$32.4K | 0.67% | 36 |
|
|
2025
Q1 | $42.9M | Buy |
1,107,923
+31,343
| +3% | +$1.15M | 0.9% | 29 |
|
|
2024
Q4 | $36.4M | Buy |
1,076,580
+179,174
| +20% | +$6.45M | 0.83% | 35 |
|
|
2024
Q3 | $36.7M | Buy |
897,406
+143,871
| +19% | +$5.89M | 0.9% | 35 |
|
|
2024
Q2 | $29M | Buy |
753,535
+16,350
| +2% | +$688K | 0.79% | 42 |
|
|
2024
Q1 | $31.6M | Sell |
737,185
-58,256
| -7% | -$2.4M | 0.83% | 38 |
|
|
2023
Q4 | $29.5M | Buy |
795,441
+230,694
| +41% | +$8.28M | 0.75% | 42 |
|
|
2023
Q3 | $20.5M | Buy |
564,747
+165,317
| +41% | +$5.87M | 0.54% | 46 |
|
|
2023
Q2 | $14.2M | Buy |
399,430
+80,270
| +25% | +$2.88M | 0.37% | 55 |
|
|
2023
Q1 | $11.4M | Buy |
319,160
+82,127
| +35% | +$2.87M | 0.27% | 54 |
|
|
2022
Q4 | $8.33M | Buy |
237,033
+53,489
| +29% | +$1.78M | 0.24% | 62 |
|
|
2022
Q3 | $5.4M | Sell |
183,544
-22,986
| -11% | -$871K | 0.15% | 67 |
|
|
2022
Q2 | $11.2M | Sell |
206,530
-172
| -0.1% | -$9.49K | 0.28% | 54 |
|
|
2022
Q1 | $11.3M | Buy |
206,702
+63,865
| +45% | +$3.47M | 0.27% | 52 |
|
|
2021
Q4 | $7.87M | Buy |
+142,837
| New | +$7.43M | 0.17% | 62 |
|
|
2019
Q2 | – | Sell |
-1,138
| Closed | -$59K | – | 91 |
|
|
2019
Q1 | $59K | Sell |
1,138
-226,535
| -100% | -$11.3M | ﹤0.01% | 85 |
|
|
2018
Q4 | $10.9M | Sell |
227,673
-84,311
| -27% | -$4.15M | 0.13% | 57 |
|
|
2018
Q3 | $15.7M | Sell |
311,984
-30,837
| -9% | -$1.57M | 0.16% | 53 |
|
|
2018
Q2 | $17.3M | Sell |
342,821
-393,801
| -53% | -$19.8M | 0.17% | 53 |
|
|
2018
Q1 | $36M | Buy |
736,622
+232,492
| +46% | +$10.8M | 0.39% | 40 |
|
|
2017
Q4 | $22.4M | Buy |
504,130
+63,402
| +14% | +$2.93M | 0.24% | 48 |
|
|
2017
Q3 | $22.4M | Buy |
440,728
+100,690
| +30% | +$5.11M | 0.25% | 46 |
|
|
2017
Q2 | $18.3M | Buy |
340,038
+87,626
| +35% | +$4.67M | 0.23% | 45 |
|
|
2017
Q1 | $13.3M | Buy |
252,412
+16,764
| +7% | +$850K | 0.18% | 50 |
|
|
2016
Q4 | $11M | Sell |
235,648
-26,287
| -10% | -$1.3M | 0.19% | 54 |
|
|
2016
Q3 | $14.1M | Sell |
261,935
-1,906
| -0.7% | -$105K | 0.26% | 50 |
|
|
2016
Q2 | $14.3M | Sell |
263,841
-96,483
| -27% | -$5.08M | 0.3% | 50 |
|
|
2016
Q1 | $19.3M | Sell |
360,324
-54,296
| -13% | -$2.7M | 0.44% | 40 |
|
|
2015
Q4 | $20.9M | Sell |
414,620
-70,432
| -15% | -$3.59M | 0.44% | 45 |
|
|
2015
Q3 | $23.3M | Buy |
485,052
+78,947
| +19% | +$4.11M | 0.47% | 42 |
|
|
2015
Q2 | $21.1M | Buy |
406,105
+54,414
| +15% | +$3.06M | 0.53% | 42 |
|
|
2015
Q1 | $20.3M | Buy |
+351,691
| New | +$20.2M | 0.53% | 41 |
|
Other funds holding GSK
JEST
Sarah Ketterer's GSK Position: Q2 2026 in Review
Sarah Ketterer reduced its GSK (GSK) stake by 36% in Q2 2026, selling an estimated $209K and leaving 7,163 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #106.
Sarah Ketterer first reported a position in GSK in Q1 2015 and has held it in 36 quarters since. The position peaked at $50.8M in Q3 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Sarah Ketterer held 7,163 shares of GSK worth $375K as of Q2 2026.
- Sarah Ketterer sold 3,947 GSK shares in Q2 2026, an estimated $209K.
- GSK made up ﹤0.01% of Sarah Ketterer's portfolio in Q2 2026, its #106 holding.
- Sarah Ketterer first reported a position in GSK in Q1 2015 and has held it in 36 quarters since.
- Sarah Ketterer's GSK position peaked at $50.8M in Q3 2025.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Causeway Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.